Artemisinin-resistant malaria in Ethiopia: who’s at risk and why it matters
Official title: Epidemiology and determinants of emerging artemisinin-resistant malaria in Ethiopia
Funded at Univ of North Carolina Chapel Hill · NIH-11542575 · Data updated 2026-11-12
This grant looks at why some malaria parasites in Ethiopia are harder to treat with standard artemisinin-based medicines and what that means for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | June 9, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $82,080 |
| NIH project number | 3R01AI177791-04S1 |
| Project ID | NIH-11542575 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with falciparum malaria presenting at participating health facilities in Ethiopia.
✕Less likely to help
Patients treated with non-resistant parasites or in areas outside the study sites may not directly benefit.
What this research studies
Researchers will study how and why parasites with artemisinin resistance spread in Ethiopia by surveying patients at health facilities and analyzing parasite genetics and diagnostics. The project partners with Ethiopian health authorities and universities to collect samples, track treatment outcomes, and identify risk factors for resistant infections. Findings could inform better clinical management, diagnostics, and policy decisions to protect malaria patients in the region. Patients may benefit from improved diagnosis and treatment strategies based on these insights.
Why it matters
Potential benefit: If successful, the work could lead to more effective treatments and diagnostics for malaria patients in Ethiopia and similar settings.
How similar studies have gone: Previous work has shown that resistant strains can arise and spread, but this study focuses on specifics in the Horn of Africa and local determinants, making its results particularly informative.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Parr, Jonathan Boyd — Univ of North Carolina Chapel Hill
- Study coordinator: Parr, Jonathan Boyd
Related research
Other NIH-funded projects on the same topics.
-
Digital malaria surveillance in Ethiopia to improve outbreak detection
A collaboration to add a malaria-specific digital module to an existing surveillance system in Africa to help detect and respond to outbreaks faster.
-
Cross-sector partnership uses digital malaria surveillance in Ethiopia
A US-based team will adapt and test a digital malaria surveillance module in SORMAS to help detect and respond to malaria outbreaks in Ethiopia.
-
Malaria control project in Western Kenya to reduce illness and deaths
A large, multi-year effort in western Kenya will help track malaria spread and test ways to prevent transmission so fewer people get sick or die.
-
Optimizing tafenoquine dose to prevent relapse of vivax malaria in Asia
A study tests the best tafenoquine dose to prevent P. vivax malaria relapse in people in East Asia and Oceania.
-
Optimizing tafenoquine dose to prevent P. vivax malaria relapses in Asia
A study to find the best single-dose tafenoquine amount to prevent relapse of P. vivax malaria in people in East Asia and Oceania.
-
Severe malaria and brain risk in children
This grant studies how severe malaria in young children can affect brain development and long-term thinking and behavior, with a focus on kids in Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.